Axsome Therapeutics(US:AXSM) ZACKSยท2025-02-11 16:06Company Overview - Axsome Therapeutics (AXSM) is anticipated to report a year-over-year decline in earnings despite higher revenues for the quarter ended December 2024, with a consensus outlook indicating a loss of $0.97 per share, representing a -32.9% change from the previous year [1][3] - Revenues are expected to reach $117.84 million, reflecting a significant increase of 64.7% compared to the same quarter last year [3] Earnings Expectations - The earnings report is scheduled for release on February 18, 2025, and could influence the stock price depending on whether the actual results exceed or fall short of expectations [2] - The consensus EPS estimate has been revised 1.63% lower in the past 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][10] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates an Earnings ESP of -4.06% for Axsome, suggesting that the Most Accurate Estimate is lower than the Zacks Consensus Estimate [10][11] - Historically, Axsome has beaten consensus EPS estimates in the last four quarters, with a recent surprise of +2.90% when it reported a loss of $1.34 per share against an expected loss of $1.38 [12][13] Industry Comparison - In contrast, Blueprint Medicines (BPMC), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report an EPS of $0.51 for the same quarter, marking a +72% year-over-year change, with revenues projected at $147.53 million, up 105% from the previous year [17] - Despite a positive outlook, Blueprint Medicines also faces a challenging Earnings ESP of -72.80%, combined with a Zacks Rank of 3, making it difficult to predict an earnings beat [18]